Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

CategoryBioTech
Employees

Offices

People

President and CEO
Board Member

Funding

TOTAL $45.6M
FUNDING TOTAL $45.6M
Partial Close, 12/2012
Canaan Partners
InterWest Partners
Sofinnova Ventures
$14.6M
Series A, 1/2013
venBio
Canaan Partners
InterWest Partners
Sofinnova Ventures
$31M

Tags

Labrys Biologics

Labrys Biologics Inc., a company focused on treatments for chronic migraine.

Labrys Biologics has acquired worldwide rights to RN-307 from Pfizer Inc. RN-307 is an antibody for the treatment of chronic migraine.

RN-307 was originally developed by Rinat Pharmaceuticals, acquired by Pfizer in 2006.

Recent Milestones

Videos

Screenshots

Sources

  1. SEC (sec.gov) [edit]
  2. Labrys Biologics Completes $31M Series A Financing (finsmes.com) [edit]
Edit This Page
Last Edited 3/4/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy